| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
13,680,000 |
| Market
Cap: |
3.49(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.1322 - $0.67 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TRACON Pharmaceuticals is a biopharmaceutical company. Co. has a collaboration and clinical trial agreement for the development of envafolimab, an investigational PD-L1 single-domain antibody for the treatment of soft tissue sarcoma in North America. Other clinical stage oncology product candidates include: YH001, which is a monospecific investigational CTLA-4 antibody, that Co. licensed from Eucure (Beijing) Biopharma Co., Ltd. and Biocytogen Pharmaceuticals (Beijing) Co., Ltd., TRC102, which is a small molecule for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors, and TJ004309, which is a CD73 antibody for the treatment of solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,418,993 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,892,637 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
30 |
| Total Shares Sold |
0 |
0 |
4,764,008 |
4,765,667 |
| Total Sell Value |
$0 |
$0 |
$1,401,571 |
$1,403,938 |
| Total People Sold |
0 |
0 |
1 |
2 |
| Total Sell Transactions |
0 |
0 |
1 |
3 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Theuer Charles |
President and CEO |
• • – |
2019-08-09 |
4 |
B |
$0.45 |
$22,500 |
D/D |
50,000 |
173,565 |
2.81 |
- |
|
| Theuer Charles |
President and CEO |
• • – |
2019-01-22 |
4 |
D |
$1.04 |
$9,663 |
D/D |
(9,290) |
123,565 |
|
- |
|
| Theuer Charles |
President and CEO |
• • – |
2018-12-21 |
4 |
B |
$0.66 |
$32,222 |
D/D |
49,000 |
132,855 |
2.81 |
- |
|
| Wang Theodore T |
Director |
– • • |
2018-11-29 |
4 |
S |
$1.21 |
$5,234 |
I/I |
(4,326) |
4,601,768 |
|
- |
|
| Wang Theodore T |
Director |
– • • |
2018-11-29 |
4 |
B |
$1.13 |
$4,888 |
I/I |
4,326 |
4,606,094 |
2.17 |
- |
|
| Nea 14 Gp, Ltd |
10% Owner |
– – • |
2018-03-27 |
4 |
B |
$2.70 |
$1,911,503 |
D/D |
707,964 |
3,466,003 |
2.45 |
- |
|
| Nea 14 Gp, Ltd |
10% Owner |
– – • |
2018-03-27 |
4 |
B |
$2.70 |
$1,911,503 |
I/I |
707,964 |
3,466,003 |
1.5 |
- |
|
| Theuer Charles |
President and CEO |
• • – |
2018-01-22 |
4 |
D |
$2.95 |
$27,406 |
D/D |
(9,290) |
76,855 |
|
- |
|
| Bitar Patricia L |
CFO |
• – – |
2018-01-22 |
4 |
D |
$2.95 |
$9,785 |
D/D |
(3,317) |
29,636 |
|
- |
|
| Logan H Casey |
Chief Business Officer |
• – – |
2018-01-22 |
4 |
D |
$2.95 |
$9,785 |
D/D |
(3,317) |
27,754 |
|
- |
|
| Larue William R |
Director |
– • – |
2017-06-02 |
4 |
AS |
$2.69 |
$6,733 |
D/D |
(2,500) |
13,388 |
|
- |
|
| Logan H Casey |
Chief Business Officer |
• – – |
2017-01-23 |
4 |
D |
$4.85 |
$17,227 |
D/D |
(3,552) |
31,071 |
|
- |
|
| Bitar Patricia L |
CFO |
• – – |
2017-01-23 |
4 |
D |
$4.85 |
$17,227 |
D/D |
(3,552) |
30,543 |
|
- |
|
| Baskett Forest |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Barrett M James |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Florence Anthony A. Jr. |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Barris Peter J |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Kerins Patrick J |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Kolluri Krishna Kittu |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Sandell Scott D |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Mott David M |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Viswanathan Ravi |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Sonsini Peter W. |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
2,758,039 |
1.5 |
- |
|
| Nea 14 Gp, Ltd |
10% Owner |
– – • |
2016-11-29 |
4 |
B |
$5.75 |
$4,999,999 |
D/D |
869,565 |
2,758,039 |
2.45 |
- |
|
| Shazer Ronald L |
Chief Medical Officer |
• – – |
2016-06-03 |
4 |
AS |
$7.48 |
$7,502 |
D/D |
(1,003) |
335 |
|
- |
|
241 Records found
|
|
Page 6 of 10 |
|
|
